Organisation paid for research Program year 2025 Source: CMS Open Payments

Brain Matters Research

Neither a doctor nor a teaching hospital

Research payments

$3,482,694

439 payments

Through program year 2025, Brain Matters Research is reported as receiving $3,482,694 in research payments, across 439 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $84,087 10
2024 Research $841,710 325
2023 Research $941,039 46
2022 Research $509,408 17
2021 Research $366,822 31
2020 Research $88,492 8
2019 Research $651,135 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $1,996,429 124 payments
  2. Biogen, Inc. $731,076 6 payments
  3. Novartis Pharmaceuticals Corporation $693,685 4 payments
  4. Novo Nordisk AS $54,318 298 payments
  5. Merck Sharp & Dohme Corporation $5,705 2 payments
  6. AbbVie, Inc. $1,480 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,618,754 65 payments
  2. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $693,426 4 payments
  3. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $367,573 2 payments
  4. A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia $326,112 2 payments
  5. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $212,040 23 payments
  6. A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid $67,878 20 payments
  7. Nn6535-7519 $54,318 298 payments
  8. AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $50,700 7 payments
  9. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $47,057 9 payments
  10. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $37,650 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record